title: The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
abstract: The purpose of this study was to investigate the relation between the standardised uptake value (SUV) on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan and hypoxia related markers (HIF-1alpha and CAIX), a proliferation-related marker (Ki-67) and glucose transporters (GLUT-1 and GLUT-3) in non-small cell lung cancer (NSCLC). One hundred and two patients, scheduled for complete resection, received a PET scan in Leuven or Maastricht/Aachen. The maximal SUV (SUV(max)) was correlated with survival and immunohistochemical staining patterns. The actuarial survival was worse for patients showing a high SUV(max), the best discriminative value being 8.0 (Leuven, p=0.032) and 11.0 (Maastricht, p=0.007). Tumours with a high SUV(max) expressed in a higher proportion HIF-1alpha (63.1% versus 37.9%, p=0.024) and GLUT-1 (82.9% versus 62.5%, p=0.025), than tumours with a low SUV(max). No significant difference was found in the expression of CAIX, Ki-67 and GLUT-3. This study supports preclinical data that hypoxia is associated with a higher uptake of FDG.
authors.affiliation: Department of Radiation Oncology (MAASTRO), GROW, University Hospital Maastricht, Dr. Tanslaan 12, 6229 ET Maastricht, The Netherlands. angela.vanbaardwijk@maastro.nl
authors.forename: Angela
authors.initials: A
authors.lastname: van Baardwijk
authors.forename: Christophe
authors.initials: C
authors.lastname: Dooms
authors.forename: Robert Jan
authors.initials: RJ
authors.lastname: van Suylen
authors.forename: Erik
authors.initials: E
authors.lastname: Verbeken
authors.forename: Monique
authors.initials: M
authors.lastname: Hochstenbag
authors.forename: Cary
authors.initials: C
authors.lastname: Dehing-Oberije
authors.forename: Dennis
authors.initials: D
authors.lastname: Rupa
authors.forename: Silvia
authors.initials: S
authors.lastname: Pastorekova
authors.forename: Sigrid
authors.initials: S
authors.lastname: Stroobants
authors.forename: Ulrich
authors.initials: U
authors.lastname: Buell
authors.forename: Philippe
authors.initials: P
authors.lastname: Lambin
authors.forename: Johan
authors.initials: J
authors.lastname: Vansteenkiste
authors.forename: Dirk
authors.initials: D
authors.lastname: De Ruysscher
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D051272:Glucose Transporter Type 1 / Q000378:metabolism*; D051274:Glucose Transporter Type 3 / Q000378:metabolism; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods / Q000401:mortality; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18